Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
The Oncologist · 06.04.2023 · 28 (4) · 319-326
DOI: 10.1093/oncolo/oyad025 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 02.03.2023. Verfasst von Natalie Danziger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Foundation Medicine, Inc., Cambridge, MA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background
In 2020, pembrolizumab was approved as a therapy for triple-negative breast cancer (TNBC) with the companion diagnostic DAKO 22C3 programmed death ligand-1 (PD-L1) immunohistochemistry assay. The study aimed to determine the landscape of PD-L1 expression as detected by the DAKO 22C3 PD-L1 assay in breast cancer subtypes and compare the clinicopathologic and genomic characteristics of PD-L1 positive and negative TNBC.
Methods
PD-L1 expression using the DAKO 22C3 antibody was scored using a combined positive score (CPS) and positive status was defined as CPS ≥10. Comprehensive genomic profiling was performed using the FoundationOne CDx assay.
Results
Of the 396 BC patients stained with DAKO 22C3, the majority were HR+/HER2− and TNBC (42% and 36%, respectively). Median PD-L1 expression and frequency of CPS ≥10 was highest in TNBC cases (median: 7.5, 50% CPS ≥10) and lowest in the HR+/HER2− group (median: 1.0, 15.5% CPS ≥10) (P < .0001). A comparison of PD-L1 positive and PD-L1 negative TNBC demonstrated no significant differences in clinicopathologic or genomic characteristics. TNBC tissue samples from the breast did have an observed enrichment for PD-L1 positivity compared to TNBC tissue samples from a metastatic site (57% vs. 44%), but this was not statistically significant (P = .1766). In the HR+/HER2− group, genomic alterations in TP53, CREBBP, and CCNE1 were more prevalent and genomic loss of heterozygosity was higher in the PD-L1(+) group compared to the PD-L1(−) group.
Conclusions
The subtypes of breast cancer have distinct patterns of PD-L1 expression, supporting that further research of immunotherapies may include specific evaluation of optimum cutoffs for non-TNBC patients. In TNBC, PD-L1 positivity is not associated with other clinicopathologic or genomic features and should be integrated into future studies of immunotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foundation Medicine, Inc., Cambridge, MA, USA.
- Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
- The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Liverpool, UK.
- Departments of Pathology and Urology, State University of New York Upstate Medical University, Syracuse, NY, USA.
ORCID-Profile: Lajos Pusztai, Richard S P Huang
Förderung
- NCATS NIH HHS
Zitieren
APA
Danziger, N., Sokol, E. S., Graf, R. P., Hiemenz, M. C., Maule, J., Parimi, V., Palmieri, C., Pusztai, L., Ross, J. S., & Huang, R. S. P. (2023). Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. The Oncologist, 28(4), 319-326. https://doi.org/10.1093/oncolo/oyad025
Vancouver
Danziger N, Sokol ES, Graf RP, Hiemenz MC, Maule J, Parimi V, et al. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. The Oncologist. 2023;28(4):319-326. doi:10.1093/oncolo/oyad025
BibTeX
@article{Danziger2023,
author = {Danziger, Natalie and Sokol, Ethan S and Graf, Ryon P and Hiemenz, Matthew C and Maule, Jake and Parimi, Vamsi and Palmieri, Carlo and Pusztai, Lajos and Ross, Jeffrey S and Huang, Richard S P},
title = {Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {4},
pages = {319--326},
doi = {10.1093/oncolo/oyad025}
}
EUVIMED